Zacks SCR - Co-Host 

Zacks Small-Cap Research, a preferred provider in the OTC Markets Group’s Research Marketplace, prepares independent company-sponsored research and related content for distribution through a multitude of investor and media channels, both traditional and social, delivering broad awareness worldwide among serious, long-term investors.  We have a team of 6 life sciences-qualified analysts creating deep understanding of companies, hopefully generating significant interest in investment through the depth of their research and the breadth of our distribution.  Please visit our website https://scr.zacks.com to evaluate all.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) 

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biopharmaceutical company developing cancer treatments using its proprietary INTASYL® technology, a patented form of siRNA (short interfering RNA) gene silencing that works by switching off specific genes that allow tumors to evade the immune system. Rather than attacking cancer cells directly, INTASYL reactivates the body's own T cells, a type of immune cell, so they can more effectively identify and kill tumors. Phio's lead program, PH-762, targets the PD-1 gene in skin cancer and completed the treatment phase of a Phase 1b clinical trial in January 2026, with 22 patients treated across five escalating dose cohorts. A second program, PH-894, targets the BRD4 gene across a broader range of cancers and has completed the studies required to file for FDA authorization to begin clinical testing. Phio holds 59 issued patents with protection extending to 2044 and carries no debt.

Prostatype Genomics AB (OTCQB: PGABF | NASDAQ Stockholm: PROGEN)

Prostate cancer is one of the most common forms of cancer and approximately 1.3 million men are diagnosed annually. Prostatype Genomics AB specializes in the development, manufacturing, and marketing of the prognostic genetic test Prostatype®. Prostatype® is a genetic test that provides a comprehensive assessment of the aggressiveness of prostate cancer.

MetaVia Inc. (NASDAQ: MTVA)

MetaVia is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist circumference reduction. Vanoglipel is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.

Jaguar Health, Inc. (Nasdaq: JAGX)

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo Pharmaceuticals’ crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about Jaguar Health, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo Therapeutics, visit napotherapeutics.com. For more information about Magdalena Biosciences, visit magdalenabiosciences.com.

Protalix BioTherapeutics, Inc. (NYSE American PLX) 

Protalix is a biopharmaceutical company focused on the development, production, and commercialization of innovative medicines for patients living with rare diseases. We are advancing promising candidates leveraging our expertise in protein therapeutics through our proprietary, commercial-scale ProCellEx® plant cell-based protein expression system, as well as our chemical and genetic modification capabilities, including PEGylation. With two approved drugs already making an impact, we are committed to expanding our pipeline to address the unmet needs of patients facing some of the most challenging rare diseases.

Nasus Pharma Ltd. (NYSE American: NSRX)

Nasus Pharma is a clinical-stage biopharmaceutical company developing innovative intranasal drug delivery products. Uniquely positioned to address medical emergencies, Nasus Pharma’s Proprietary Nasax® technology is designed to enhance intranasal drug absorption with a potential for longer drug product shelf-life via a unique powder formulation.

CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, with more than 300,000 CytoSorb® devices sold in more than 70 countries to date, and seeking U.S. FDA market authorization for an investigational product, DrugSorb-ATR®, to remove blood thinning drugs.

PetVivo Holdings Inc. (OTCQX: PETV) 

PetVivo is a veterinary biotech and biomedical device company primarily engaged in the business of translating or adapting human biotech and medical technology into products for commercial sale in the veterinary market to help companion animals such as dogs and horses suffering from arthritis and other afflictions. 

Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) 

Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries. 

Abingdon Health plc (OTCQB: ABDXF | LSE: ABDX) 

Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base.  

The Group's CDMO (Contract Development and Manufacturing Organisation) expertise offers lateral flow product development, regulatory strategy support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format.  Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from idea to commercial success.

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring.  The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other in vitro diagnostic assays from its Doncaster, England facilities.

Founded in 2008, Abingdon Health is headquartered in York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.

Abingdon Health's brochures outlines the comprehensive support the Group can now provide to its international customers.  For more information visit: www.abingdonhealth.com.

Innovotech, Inc. (OTCQ BIOTCF TSXV IOT) logo

Innovotech Inc. is a Canadian boutique contract research organization specializing in advanced laboratory services and commercializing proprietary technologies. A leader in biofilm science, the company provides expertise in antimicrobial testing, pharmaceutical analysis, and industrial laboratory solutions, supported by innovative methodologies and products including its widely-used MBEC Assay® kit for high-throughput antimicrobial and antibiotic testing. Innovotech Inc. serves clients across multiple sectors, delivering customized research and testing services designed to meet rigorous regulatory and scientific standards such as those of the U.S. Food and Drug Administration and Health Canada through its ISO-certified and GMP-accredited laboratories.

Lakewood-Amedex Biotherapeutics Inc. (Nasdaq LABT) image

Lakewood-Amedex Biotherapeutics Inc. is focused on developing the next-generation of topical antimicrobials to address some of the most significant unmet medical needs in the treatment of infectious diseases. With high excellence in drug development capabilities and aiming for first-in-class commercialization of our lead compound, we are leading the way to develop treatment options which help to overcome the bacterial resistance crisis and may also advance the treatment of non-bacterial infectious diseases.

Kelyniam Global, Inc. (OTCID KLYG) logo

Kelyniam is an industry leader in delivering custom cranial and craniofacial implants within 24-48 hours of surgeon approval for RUSH and Expedited cases.

This service allows for a decreased hospital length of stay for in-house patients, and in-turn a decreased risk of infection.

Designed and manufactured in the United States, our implants meet the highest standards of precision, safety, and reliability.

Surgeons trust Kelyniam to deliver patient implants on time, every time.

IMUNON, Inc. (Nasdaq: IMNN) 

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. 

Promino Nutritional Sciences Inc. (OTCID MUSLF  CSE MUSL) image

Promino Nutritional Sciences is a Canadian innovation company focused on science-based, clinically proven nutrition for muscle health and recovery. Its core product, Rejuvenate Muscle Health™, is a clinically researched proprietary amino acid formula designed to rebuild, restore, and rejuvenate muscle tissue.  

The Company also produces Promino™ – NSF Certified for Sport®, trusted by elite athletes. Promino’s ambassadors include Stanley Cup Champion Jack Eichel (Vegas Golden Knights) and MLB legend José Bautista.   Learn more at www.drinkpromino.com and www.rejuvenatemuscle.com.

Envoy Medical Inc. (Nasdaq : COCH) 

Envoy Medical (NASDAQ: COCH) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.

Coiled Therapeutics plc (OTCQB COTXF  AIM COIL) image

Coiled Therapeutics (AIM: COIL, OTCQB: COTXF) is an AIM-listed, clinical-stage oncology company focused on developing innovative precision therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications. Coiled Therapeutics is supported by a leadership team with a proven track record in drug development and strategic backing from A2A Pharmaceuticals.

Aspire Biopharma Holdings Inc. (NASDAQ: ASBP) 

Aspire Biopharma is developing next generation delivery of medicine that could have a significant impact on the opioid crisis. Our nano technology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tract.

Aspire’s technology comes from a new mechanism of action which allows for rapid absorption under the tongue. Benefits of “rapid absorption” are to provide nearly fast treatment impact and also allows high dose absorption.

Our technology can be applied to any number of proven drugs and supplements, such as analgesics, erectile dysfunction, and traumatic brain injury drugs.

Rocket Doctor AI Inc. (OTCQB: AIRDF | CSE: AIDR) 

Rocket Doctor AI Inc. delivers physician-built, AI-powered solutions designed to make high-quality healthcare accessible throughout the entire patient journey. A cornerstone of the company’s proprietary technology is the Global Library of Medicine (GLM), a clinically validated decision support system developed with input from hundreds of physicians worldwide. Alongside the GLM is Rocket Doctor Inc, and its AI-powered digital health platform and marketplace. Having helped empower over 350 MDs to provide care to more than 750,000 patient visits, our proprietary technology software and systems enable doctors to independently launch and manage their own virtual or hybrid in-person practices – improving efficiency, restoring autonomy to MDs, and expanding patient access to care.

By reducing administrative burdens and ensuring greater consistency in care, our technology creates more time for meaningful physician-patient interactions. We are committed to reaching underserved, rural, and remote communities in Canada who often lack access to family doctors and supporting patients on Medicaid and Medicare in the United States. With advanced AI, large language models, and connected medical devices, Rocket Doctor AI is redefining modern healthcare - making it more scalable, equitable, and patient-centered..

aTyr Pharma, Inc. (Nasdaq: ATYR) 

aTyr Pharma is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Our lead therapeutic candidate is efzofitimod, a novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause chronic inflammation and progressive fibrosis, or scarring, of the lungs. We are currently investigating efzofitimod in pulmonary sarcoidosis, a major form of ILD, and systemic sclerosis (SSc, or scleroderma)-related ILD. We recently reported topline results from the global Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis, and the Phase 2 EFZO-CONNECT™ study of efzofitimod in patients with SSc-ILD is ongoing. Efzofitimod has received U.S., E.U. and Japanese Orphan Drug designations and U.S. Fast Track designation for sarcoidosis. Additionally, efzofitimod has received U.S. and E.U. Orphan Drug designations and U.S. Fast Track designation for SSc. We also have a partnership with Kyorin Pharmaceutical, Co., Ltd., with a total deal value up to $175m, for the development and commercialization of efzofitimod for ILD in Japan. In addition to efzofitimod, we have a pipeline of therapeutic candidates derived from our tRNA synthetase platform targeting inflammation and fibrosis.

NuFarm Ltd. (Pink NUFMF | ASX NUF) logo

Nufarm Limited is a global agricultural technology company headquartered in Melbourne, Australia. Listed on the Australian Securities Exchange (ASX: NUF), the company develops and markets crop protection products and seed technologies designed to help farmers improve productivity and meet growing global demand for food, feed, fiber, and fuel.